Citation Impact
Citing Papers
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Acute promyelocytic leukemia current treatment algorithms
2021
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
2012 Standout
The Impact of Commission on Cancer Accreditation Status, Hospital Rurality and Hospital Size on Quality Measure Performance Rates
2022
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Adoption of Digital Technologies in Health Care During the COVID-19 Pandemic: Systematic Review of Early Scientific Literature
2020 Standout
Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering From Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-controlled Study
2011
Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer
2022
Breast Cancer Statistics, 2022
2022 Standout
Navigating Nonessential Research Trials During COVID‐19: The Push We Needed for Using Digital Technology to Increase Access for Rural Participants?
2020
Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review
2018 Standout
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial
2021
Works of Anna Moseley being referenced
ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial
2016
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
2020
The Significance of Serial Measurement of Serum Anti-Native DNA Antibodies and Complement C3 and C4 Components in the Management of Patients with Systemic Lupus Erythematosus
1977
Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials
2018
Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).
2020
Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials
2018